Michel Baijot
Director/Board Member chez DMS IMAGING
Profil
Michel Baijot is currently the Chairman at OncoRadiomics SA, a Non-Executive Director at DMS Imaging SA, a Director at Antelope.
Dx BV, a Director at Antelope Diagnostics, and the President at White Fund SA. Previously, he served as the Executive Director-Europe Region at Serum Institute of India Pvt Ltd., the Director at IRE ELiT SRL, the Vice President-Business Development at Fujirebio Europe NV, the Vice President-Business Development at GlaxoSmithKline Biologicals NV, and the Chief Business Officer & Head-Cipla Global Vaccine at Janssen, Inc.
Postes actifs de Michel Baijot
| Sociétés | Poste | Début |
|---|---|---|
| DMS IMAGING | Director/Board Member | 01/09/2018 |
OncoRadiomics SA
 OncoRadiomics SA Investment Trusts/Mutual FundsMiscellaneous OncoRadiomics SA functions as a foundation or endowment. Its products include radiomix, distrim and virtual patient auatar. The company was founded by Ralph Leijenaar, Sean Walsh and Tulcinsky Paul on September 19, 2016 and is headquartered in Liège, Belgium. | Chairman | 01/01/2018 |
White Fund SA
 White Fund SA Investment ManagersFinance White Fund SA invests in companies located in Belgium and possibly neighbouring regions. It targets companies operating in the medical device sector. It provides financing for early stage with an investment size ranging between €2 million and €5 million per project. Exits are targeted after 5-7 years. | President | 01/01/2019 |
| Antelope Diagnostics | Director/Board Member | 01/09/2020 |
Antelope Dx BV
 Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | Director/Board Member | - |
Anciens postes connus de Michel Baijot
| Sociétés | Poste | Fin |
|---|---|---|
IRE ELiT SRL
 IRE ELiT SRL Pharmaceuticals: MajorHealth Technology IRE ELiT SRL is a company based in Fleurus, Belgium that specializes in the fabrication of radiochemical and radiopharmaceutical products, as well as providing radioactivity analysis services. The Belgian company has developed a new platform called RAMSES for real-time radiological analysis. For the past 50 years, IRE has been at the forefront of innovation in healthcare and nuclear medicine services. The company was founded in 2010 and the CEO is Erich Kollegger. | Director/Board Member | 01/01/2018 |
Serum Institute of India Pvt Ltd.
 Serum Institute of India Pvt Ltd. BiotechnologyHealth Technology Serum Institute of India Pvt Ltd. engages in the production and exportation of anti-cancer products and viral vaccines. Its products include bacterial vaccines, recombinant and combination vaccines, viral vaccines, influenza vaccines. uro-oncology, and polysaccharide conjugate vaccine. The company was founded by Cyrus S. Poonawalla in 1966 and is headquartered in Pune, India. | Corporate Officer/Principal | 01/01/2017 |
Janssen, Inc.
 Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Corporate Officer/Principal | 01/01/2014 |
GlaxoSmithKline Biologicals NV
 GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Corporate Officer/Principal | 01/06/2011 |
| ░░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DMS IMAGING | Health Technology |
| Entreprise privées | 9 |
|---|---|
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Health Technology |
Serum Institute of India Pvt Ltd.
Serum Institute of India Pvt Ltd. BiotechnologyHealth Technology Serum Institute of India Pvt Ltd. engages in the production and exportation of anti-cancer products and viral vaccines. Its products include bacterial vaccines, recombinant and combination vaccines, viral vaccines, influenza vaccines. uro-oncology, and polysaccharide conjugate vaccine. The company was founded by Cyrus S. Poonawalla in 1966 and is headquartered in Pune, India. | Health Technology |
Janssen, Inc.
Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Health Technology |
OncoRadiomics SA
OncoRadiomics SA Investment Trusts/Mutual FundsMiscellaneous OncoRadiomics SA functions as a foundation or endowment. Its products include radiomix, distrim and virtual patient auatar. The company was founded by Ralph Leijenaar, Sean Walsh and Tulcinsky Paul on September 19, 2016 and is headquartered in Liège, Belgium. | Miscellaneous |
IRE ELiT SRL
IRE ELiT SRL Pharmaceuticals: MajorHealth Technology IRE ELiT SRL is a company based in Fleurus, Belgium that specializes in the fabrication of radiochemical and radiopharmaceutical products, as well as providing radioactivity analysis services. The Belgian company has developed a new platform called RAMSES for real-time radiological analysis. For the past 50 years, IRE has been at the forefront of innovation in healthcare and nuclear medicine services. The company was founded in 2010 and the CEO is Erich Kollegger. | Health Technology |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | Technology Services |
White Fund SA
White Fund SA Investment ManagersFinance White Fund SA invests in companies located in Belgium and possibly neighbouring regions. It targets companies operating in the medical device sector. It provides financing for early stage with an investment size ranging between €2 million and €5 million per project. Exits are targeted after 5-7 years. | Finance |
| Antelope Diagnostics |
